Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man

S J KONTUREK, N Kwiecien, W Obtulowicz, B Kopp, and J Oleksy

From the Institute of Physiology, Kraków, Poland and District Hospital, Kraków, Poland

SUMMARY Two groups A and B each comprising 12 healthy young male subjects were used in a double blind, placebo controlled trial to assess the effects of 1.0 g sucralfate qid on prostaglandin (PG) generation and mucosal integrity in the intact and aspirin-treated stomach. Mucosal formation and luminal release of PGE₂, 6-keto-PGF₁₅, and thromboxane B₂, gastric microbleeding and DNA loss (integrity indicators) and basal and pentagastrin induced acid secretion were measured after placebo and sucralfate treatment in subjects without (group A) and with administration of 2.5 g aspirin (group B). Sucralfate significantly reduced spontaneous gastric microbleeding and DNA loss in group A and prevented blood loss but not DNA loss caused by aspirin in group B. The protective effects of sucralfate on spontaneous gastric microbleeding were accompanied by increased mucosal biosynthesis and luminal release of PGE₂ and 6-keto-PGF₁₅ with a reduction in release of thromboxane B₂. In aspirin treated subjects both mucosal generation and luminal release of prostaglandins and thromboxane B₂ were greatly suppressed although sucralfate treatment did not influence these prostaglandins in spite of the reduction in mucosal damage. It is concluded that sucralfate has a potent protective action on spontaneous and aspirin treated gastric microbleeding in man and that this protection may be partly because of the increased mucosal biosynthesis of prostaglandins.

Sucralfate, an aluminium salt of sucrose octasulfate, has been shown to prevent the formation of acute gastric lesions induced by various ulcerogens in experimental animals and to significantly improve gastric damage associated with the use of non-steroidal anti-inflammatory agents such as aspirin (ASA) in man. The efficacy of sucralfate in healing and reducing the recurrence of chronic gastroduodenal ulceration is supported by several clinical trials.

The mechanisms of the protective and antiulcer actions of sucralfate have not been fully explained but they have been attributed to the binding of the drug to the defective and ulcerated mucosa, the formation of a protective barrier over the eroded mucosal surface and the deactivation of pepsin. These properties, combined with the reduction in mucus permeability, enable the drug to act as an effective barrier preventing penetration of acid, pepsin and bile salts from the gastric lumen into the mucosa. In addition, recent studies in rats indicate that sucralfate may also stimulate the luminal release of prostaglandins (PGs), which are thought to contribute to the protective and ulcer healing properties of the drug. As the possible role of mucosal PGs in the action of sucralfate on the human stomach has yet to be investigated, this double blind, placebo controlled study was undertaken to examine the effects of sucralfate on the mucosal generation and luminal release of PGE₂, 6-keto-PGF₁₅, a metabolite of PGI₂, and thromboxane B₂ (TXB₂) and the loss of gastric blood and DNA (an index of cell desquamation) in intact and ASA-treated healthy subjects.
Methods

SUBJECTS
The study was approved by the Institutional Ethical Committee and informed consent was obtained from each of the subjects examined.

SELECTION OF SUBJECTS
The study was carried out on 24 male volunteers, 20–24 years (mean age 21 years) and weighing 63–77 kg bw (mean weight 75 kg). All subjects were in excellent health without any previous gastrointestinal diseases and with normal laboratory values for blood biochemistry, haematology, and urinalysis. All subjects underwent gastroduodenoscopy before the start of the trial to exclude any mucosal abnormalities and/or gastroduodenal ulcers or scars. The volunteers were divided into two groups (A and B) each comprising 12 subjects. Group A received no ASA in the first series of tests and group B received ASA in the second series of tests. One week before the trial, all medication was discontinued and alcohol was forbidden before and during the trial.

STUDY SCHEDULE
In the first series, each subject in group A underwent two treatment phases with one week of "washout" in between. The first treatment phase involved oral administration of one 1-0-g sulcrate or placebo tablet four times daily on four consecutive days. After the washout period one placebo or sulcrate tablet was likewise administered orally four times daily for four consecutive days. An additional dose of sulcrate or placebo was given on the study day (fifth day in the morning) about two hours before the test. The subjects in group B also underwent two treatment phases, each lasting four days, but in addition, 0-5 g ASA was administered about 30 minutes after each tablet of sulcrate or placebo on the day before the test and on the morning of the study day. Two hours after ingestion of the last tablet, a gastric tube with an agar-KCl electrode attached was placed in the stomach and the gastric potential difference was measured as previously described.25 The potential difference values expressed in millivolts (mV) referred to the polarity of the gastric lumen compared with that of the venous blood adjusted to zero. A venous blood sample was withdrawn to measure plasma salicylate concentrations.26 Then the rate of gastric microbleeding and DNA loss in gastric lumen were determined in three consecutive 10-minute gastric washings as previously described.27 In addition, PGE₂, 6-keto-PGF₁α and TXB₂ were examined by radioimmunoassay in gastric washings to determine the release of these metabolites of arachidonate into the gastric lumen. Blind biopsies of fundic gastric mucosa were then obtained using Quinton's biopsy tube under radiographic control. The biopsy samples (four to five) from each subject were then used to determine the capability of the mucosa to generate PGs and TXB₂ by radioimmunoassay using commercially available kits (New England Nuclear, Dreieich, FRG). Two biopsy samples were used for histological evaluation on the mucosa.

After completing the gastric washings and biopsy sampling, aspiration of the gastric contents was started. The residual volume was rejected and aspiration was continued for 30 min to determine basal acid and pepsin secretions. Intravenous infusion of pentagastrin (2 μg/kg/h) was started and gastric aspiration was prolonged for the next 60 minutes to determine maximal gastric acid secretory capacity. The validation tests were done to determine whether the amount of blood lost by the gastric mucosa could be accurately recovered by chemical determination. For this purpose duplicate tests were done in which known volumes of heparinised blood samples taken from two healthy subjects were diluted and added to the solutions of the composition identical to that used for the gastric washings. The results of the validation are shown on Table 1.

The trial material was coded and supplied in tablet form by E Merck, Darmstadt, FRG. The sulcrate tablets contained 1-0 g of the active agent, whereas the placebo tablets contained only inert ingredients of cornstarch and microcrystalline cellulose. The data were recorded in special case report forms supplied by E Merck. The code was broken after the study was completed and results sent to E Merck. The results are presented in Figures and a Table as individual data and mean values ±SEM.

Table 1 Recovery of various volumes of blood added to 1000 ml of the solution used for the gastric washouts

<table>
<thead>
<tr>
<th>Blood added to the solution µl/1000 ml</th>
<th>Blood recovered from the solution µl/1000 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-2</td>
<td>1-5 (125)</td>
</tr>
<tr>
<td>2-5</td>
<td>2-7 (108)</td>
</tr>
<tr>
<td>5-0</td>
<td>5-7 (114)</td>
</tr>
<tr>
<td>10-0</td>
<td>11-0 (110)</td>
</tr>
<tr>
<td>50-0</td>
<td>52-0 (104)</td>
</tr>
<tr>
<td>100-0</td>
<td>98-0 (98)</td>
</tr>
<tr>
<td>500-0</td>
<td>572-0 (114)</td>
</tr>
<tr>
<td>1000-0</td>
<td>1150-0 (115)</td>
</tr>
<tr>
<td>2000-0</td>
<td>2180-9 (109)</td>
</tr>
</tbody>
</table>

Values are means of two tests obtained with blood samples obtained from two healthy subjects. Numbers in parentheses indicate per cent recovery of blood added to the solution.
For analysis of laboratory results Friedman two way analysis of variance was done, supplemented when applicable by the Wilcoxon's two-sided test.

**Results**

**EFFECTS OF SUCRALFATE ON GASTRIC MUCOSAL GENERATION OF PROSTAGLANDINS AND TXB₂ AND THEIR LUMINAL RELEASE IN SUBJECTS WITH AND WITHOUT ASA ADMINISTRATION**

Mucosal generation of PGE₂ and 6-keto-PGF₁α in the subjects in group A receiving placebo without ASA averaged 583±88 and 229±17 ng/g tissue weight respectively. TXB₂ generation averaged 432±82 ng/g. Luminal release of PGE₂, 6-keto-PGF₁α and TXB₂ measured during a 30-min gastric washing period averaged 426±50, 78±9 and 310±52 ng/30 min, respectively (Table 2).

After sucralfate treatment for four days, mucosal generation of PGE₂ and 6-keto-PGF₁α increased significantly by about 40% and 48%, respectively. Similarly, luminal release of these PGs significantly rose on average by 34% and 46%, respectively. The mucosal formation of TXB₂ was not significantly affected by sucralfate but the luminal release of TXB₂ was significantly reduced by about 41% (Table 2).

In the second series of tests with the subjects in group B treated with ASA, mucosa generation of PGE₂ and 6-keto-PGF₁α as well as TXB₂ was relatively low and respective values averaged 49±8, 62±8 and 32±5 ng/g in the placebo-treated group. The release of these PGs and TXB₂ into the gastric lumen also were lower than in group A and averaged 50±9, 39±5 and 75±12 ng/30 min, respectively (Table 2). In the same subjects treated with sucralfate plus ASA, the values of mucosal and luminal PGE₂ and 6-keto-PGF₁α were not significantly different from those obtained after treatment with placebo plus ASA. Also mucosal generation of TXB₂ and its luminal release remained low (40±10 ng/g and 62±9 ng/g, respectively) as in the tests with placebo plus ASA (Table 2).

**EFFECT OF SUCRALFATE ON GASTRIC POTENTIAL DIFFERENCE, GASTRIC MICROBLEEDING AND DNA LOSS IN SUBJECTS WITH AND WITHOUT ADMINISTRATION OF ASA**

Known amounts of diluted blood added to the solution used for gastric washings were recovered within the range of 98–125% by chemical determination of haemoglobin in this solution (Table 1). In the control group – that is, group A treated with placebo in the first series, the potential difference value averaged 38.9±1.1 mV, gastric microbleeding was 20.3±5.8 μl/30 min and DNA loss was 205±48 μg/30 min. Sucralfate treatment for four days in these subjects resulted in a slight and insignificant rise in the potential difference value (44.5±1.6 mV). Both gastric microbleeding and DNA loss were significantly lower in the subjects treated with sucralfate than those treated with placebo (Fig. 1). Spontaneous microbleeding was reduced by about 55.2% and DNA loss by 32.4%. The reduction in both parameters studied occurred in 11 out of 12 subjects in this group.

In tests with placebo plus ASA in group B in the second series, the potential difference values averaged 30.0±1.2 mV, gastric microbleeding was 152.0±42.5 μl/30 min and DNA loss 480±63 μg/30 min (Fig. 2). Both gastric microbleeding and DNA loss caused by ASA were significantly higher in the

Table 2  **Effects of sucralfate or placebo on PD values, mucosal generation and luminal release of PGE₂, 6-keto-PGF₁α and TXB₂ and basal (BAO) and maximally stimulated by pentagastrin gastric acid secretion (MAO) in subjects without (group A) and with ASA administration (group B)**

<table>
<thead>
<tr>
<th>Type of tests</th>
<th>PD mV</th>
<th>Mucosal generation ng/g</th>
<th>Luminal release ng/30 min</th>
<th>Gastric secretion mmoL/L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>PGE₂</td>
<td>6-keto-PGF₁α</td>
<td>TXB₂</td>
</tr>
<tr>
<td>Without ASA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>38.9</td>
<td>583</td>
<td>±1.1</td>
<td>229</td>
</tr>
<tr>
<td>Sucralfate</td>
<td>44.5</td>
<td>817*</td>
<td>±1.6</td>
<td>340</td>
</tr>
<tr>
<td>With ASA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>30.0</td>
<td>49</td>
<td>±1.2</td>
<td>62</td>
</tr>
<tr>
<td>Sucralfate</td>
<td>36.4*</td>
<td>51</td>
<td>±1.8</td>
<td>54</td>
</tr>
</tbody>
</table>

*Significant (p<0.05) change from placebo control.
Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation

Subjects in group B compared with group A without ASA administration. Sucralfate treatment resulted in a significant increase in the potential difference value (36.4±1.8 mV) (Table 2) and in a significant reduction in gastric microbleeding by about 57% in all subjects treated. DNA loss in subjects receiving sucralfate plus ASA was not significantly different from that recorded with placebo plus ASA treatment in the subjects in the same group (group B) (Fig. 2).

Plasma concentrations of salicylate averaged 6.72±0.72 mg% in subjects with placebo and 5.69±0.81 mg% with sucralfate treatment, showing that there is no significant change in the sucralfate group.

EFFECTS OF SUCRALFATE ON FUNDIC MUCOSAL HISTOLOGY IN NORMAL AND ASA-TREATED SUBJECTS

In all normal group A subjects tested, the biopsy samples showed normal histology of fundic mucosa. In group B subjects treated with ASA plus placebo, mild superficial gastritis was observed in four of the
eight subjects. Similar histological changes were noted in the same subjects treated with ASA plus sucralfate.

Discussion

This study provides evidence that sucralfate in a therapeutic dose stimulates mucosal formation and luminal release of prostaglandins and reduces gastric microbleeding in intact and ASA treated humans.

Sucralfate has been tested previously in various experimental models of acute gastric mucosal lesions and was found to prevent mucosal damage caused by absolute ethanol, stress conditions, pylorus-ligation, indomethacin and aspirin. As the protective effects of sucralfate were observed in the dose range which hardly affected gastric acid secretion or luminal acidity, it has been postulated that this agent possesses cytoprotective properties similar to those of prostaglandins. Hollander et al reported that the protective effects of sucralfate against ethanol damage in rats were accompanied by a significant increase in the luminal concentration of PGE$_2$. As mucosal protection with sucralfate was reversed by pretreatment with indomethacin, a potent inhibitor of prostaglandin cyclooxygenase, it has been suggested that endogenous prostaglandins may mediate, at least in part, the protective action of sucralfate. As similar studies on prostaglandin release by sucralfate had not been carried out in man, we decided to examine the influence of the drug on both mucosal generation and luminal release of prostaglandins as related to their protective action on the gastric mucosa against aspirin damage.

Our results confirmed previous findings that healthy human gastric mucosa is capable of generating all major metabolites of arachidonate via the cyclooxygenase pathway in the form of PGE$_2$, 6-keto-PGF$_{1\alpha}$ (metabolite of PGI$_2$) and TXB$_2$. The major PG species formed in the mucosa and released into the gastric lumen was PGE$_2$, while 6-keto-PGF$_{1\alpha}$ was found in much smaller amounts. It is of interest that TXB$_2$ was synthesised in large quantities but its origin and significance remain obscure. TXA$_2$ is known to be formed in the blood...
Duloble blind controlled study on the effect of sucralfate on gastric prostaglandin formation

1455

(mainly in the platelets) to promote tissue damage, while thromboxane synthetase inhibitors were found to be cytoprotective. Thromboxanes released in the stomach may be involved in tissue damage by various ulcerogens such as bile salts and the balance between the protective prostaglandins of the E and I series and damaging thromboxanes might be implicated in the maintenance of gastric mucosal integrity.

Sucralfate treatment resulted in a significant increase in mucosal synthesis of PGE₂ and PGI₂ as indicated by the rise in 6-keto-PGF₁₀₀, but there were no significant changes in TXB₂ formation. Thus, sucralfate increased the ratio of protective prostaglandins to noxious TXB₂ in the mucosa. This is also reflected by the increase in luminal release of these prostaglandins accompanied by a fall in the TXB₂ contents. While the augmentation of prostaglandins in the gastric tissue could contribute to the ability of sucralfate to prevent spontaneous gastric microbleeding and DNA loss, the significance of changes in TXB₂ in the gastric mucosa and lumen is less clear. Because blood platelets appear to be the major source of TXB₂, the reduction in luminal TXB₂ after sucralfate therapy could reflect the decrease in gastric microbleeding rather than the changes in the mucosal formation of this arachidonate metabolite. Any conclusion concerning the role of the observed decrease in TXB₂ formation and release in the protective action of sucralfate would be premature.

By extrapolating the results for 30 minute gastric washouts to the whole 24 hours, the mean spontaneous and ASA provoked blood loss from the stomach in our patients averaged 0.97 and 7.3 ml/day, respectively. These relatively higher bleeding rate than in other studies are possibly because of different dosage and schedule of ASA administration and the age of subjects tested. Two of our subjects bled spontaneously and after ASA about three times higher than the rest of subjects. Endoscopy carried out in these subjects before the examination did not reveal any mucosal abnormalities. The reason for such higher bleeding after ASA in some subjects is not obvious but as in other studies it represents a marked variation in the bleeding rate among the subjects.

Our study indicates that sucralfate greatly reduced both spontaneous and ASA-evoked gastric microbleeding. This protective action of sucralfate is in keeping with clinical reports in man showing that it is highly effective in the improvement of both gastric lesion healing and symptoms associated with the use of various non-steroidal anti-inflammatory agents. The protective effects of sucralfate against ASA-induced gastric damage cannot be entirely attributed to mucosal prostaglandins as their generation was greatly suppressed by ASA and sucralfate did not interfere with cyclooxygenase inhibition by ASA.

Because ASA induced mucosal damage depends on gastric acid secretion and can be prevented by potent inhibitors such as ranitidine, additional secretory tests were done to find out what effect, if any, sucralfate has on gastric secretion. Both basal and maximally stimulated gastric acid and pepsin secretions were similar in the placebo and sucralfate treated subjects with and without ASA administration. Thus, we can exclude the mediation of decreased gastric secretion in the protective action of sucralfate.

Sucralfate ingestion could interfere with the absorption of ASA but similar blood concentrations of salicylate in subjects on sucralfate or placebo and ASA treatment militates against this possibility. As suggested by Slomiany et al sucralfate may change the viscoelastic properties of the gastric mucus and retard the penetration of acid and pepsin through the mucus coat to provide better protection of the underlying surface epithelium cells. Thus, sucralfate protective properties against aspirin damage seem to be unrelated to mucosa prostaglandins, possibly involving the strengthening of the mucus and mucosal barrier of the stomach.

References

1 Shimizu M, Ishii A, Imai T. Experimental studies on antiulcerous activity of basic sucrufate/CG-A6J/.


